Related Experiment Video
Updated: Jun 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Hepatic failure-induced hypogonadism in a prostate cancer patient
Chien-Chang Li1, Chi-Rei Yang, Cheng-Chan Yu
1National Chung-Hsing University, Taichung, Taiwan, R.O.C.
Abstract:
Hypogonadism owing to systemic diseases in prostate cancer is rare. Here, we present a patient with metastatic prostate cancer to the pericardium who had low serum testosterone level due to hepatic failure. The patient had cardiac tamponade, and pericardiocentesis revealed sanguineous exudate. Cytology revealed adenocarcinoma. High serum prostate-specific antigen level of 244 ng/mL was detected. The patient experienced complications of stress gastric and duodenal ulcer perforation and underwent subtotal gastrectomy. Perioperative intra-abdominal inflammatory process caused subsequent cholestasis and hepatic dysfunction. Transrectal ultrasound-guided prostate biopsy confirmed prostate cancer. Hypogonadism and a gradual decline in prostate-specific antigen were detected without any hormone therapy. The patient died due to hepatic failure in the 12(th) postoperative week.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Infertility in Males
Cirrhosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
